Evaluating the Efficacy of Chronic Galantamine on Sustained Attention and Cholinergic Neurotransmission in A Pre-Clinical Model of Traumatic Brain Injury.

Authors

• Eleni H Moschonas
• Haley E Capeci
• Ellen M Annas
• Veronica B Domyslawski
• Jade A Steber
• Hailey M Donald
• Nicholas R Genkinger
• Piper L Rennerfeldt
• Rachel A Bittner
• Vincent J Vozzella
• Jeffrey P Cheng
• Anthony E Kline
• Corina O Bondi

Publication/Presentation Date

11-1-2024

Abstract

Cholinergic disruptions underlie attentional deficits following traumatic brain injury (TBI). Yet, drugs specifically targeting acetylcholinesterase (AChE) inhibition have yielded mixed outcomes. Therefore, we hypothesized that galantamine (GAL), a dual-action competitive AChE inhibitor and α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator, provided chronically after injury, will attenuate TBI-induced deficits of sustained attention and enhance ACh efflux in the medial prefrontal cortex (mPFC), as assessed by

Volume

41

Issue

21-22

First Page

2428

Last Page

2441

ISSN

1557-9042

Published In/Presented At

Moschonas, E. H., Capeci, H. E., Annas, E. M., Domyslawski, V. B., Steber, J. A., Donald, H. M., Genkinger, N. R., Rennerfeldt, P. L., Bittner, R. A., Vozzella, V. J., Cheng, J. P., Kline, A. E., & Bondi, C. O. (2024). Evaluating the Efficacy of Chronic Galantamine on Sustained Attention and Cholinergic Neurotransmission in A Pre-Clinical Model of Traumatic Brain Injury. Journal of neurotrauma, 41(21-22), 2428–2441. https://doi.org/10.1089/neu.2024.0173

Disciplines

Medicine and Health Sciences

PubMedID

38994598

Department(s)

Medical Education

Document Type

Article